Genmab

	23/1 09:38 af Darvin	3640 på 12 mdr er da også Ok ;-) 32,8% op herfra kan jeg såmænd godt leve med
	23/1 08:50 af Mogan	Godmorgen: Ja, ja.. vi fik da lov at være lidt glade i weekenden med info fra gentogen. HCM´s nedgradering var så "modsvaret", dog fra et meget højt niveau. Jeg er stadig positiv på casen og har de lange briller på, selv om de engang imellem skal pudses :-)
	23/1 08:26 af JKY_VH	"STOCKHOLM (Nyhetsbyrån Direkt) Handelsbanken Capital Markets sänker sin rekommendation för det danska läkemedelsbolaget Genmab till market perform från outperform. Riktkursen sänks till 3.640 från 4.465 danska kronor. Det framgår av en uppdatering från banken. Aktien stängde på 2.740 danska kronor i Köpenhamn föregående handelsdag."
	23/1 08:10 af JKY_VH	Tak gentogen og god morgen til alle;-)
	23/1 07:26 af Stroka	God morgen :-)
	23/1 07:16 af Helge Larsen/PI-redaktør	Ditto her fra og godmorgen :-)
	23/1 04:35 af StockBull	Morn, kanon info gentogen. Så vare det jo nok ikke længe inden peaksales bliver hævet til +20 mia og resten af pipelinen ser også ud til at være undervurderet. Novod har senest hævet Rybrevant og Tivdak pænt. Mon ikke vi ser det samme med Epco de kommende år
	22/1 21:57 af Solsen	Tak gentogen !
	22/1 18:39 af gdn55	Enig, spændende fremtid
	22/1 16:00 af Darvin	Tak igen Gentogen. Dejlige klip, og tænker der er meget at se frem til, og andet end JJ relateret
	22/1 10:51 af Bulder	Du burde ha' en flidspræmie, gentogen. Sidder oppe lørdag nat og finder Guldkorn. Tak for det. :-)
	22/1 02:38 af transalp	Det lyder sguda vildt, gentogen..
	22/1 01:53 af gentogen	Antallet af videnskabelige artikler om daratumumab er helt vildt.Alle de nævnte er fra 2023 og et kun en lille bitte del af uendelig meget mere
	22/1 01:52 af gentogen	CHEST, Volume 163, Issue 1, January 2023, Pages e1-e5
	22/1 01:51 af gentogen	This is the first report of the successful use of daratumumab in dermatomyositis. It highlights the potential of CD38 targeted therapies for severe antibody-mediated autoimmune diseases such as dermatomyositis.
	22/1 01:50 af gentogen	Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis is a rare systemic autoimmune disease that is associated with life-threatening rapidly progressive interstitial lung disease.....Rescue therapy with daratumumab, an anti-CD38-antibody, was initiated. Significant pulmonary improvement was noticed after 4 weekly injections
	22/1 01:49 af gentogen	Successful Rescue Therapy With Daratumumab in Rapidly Progressive Interstitial Lung Disease Caused by MDA5-Positive Dermatomyositis
	22/1 01:45 af gentogen	(link)
	22/1 01:45 af gentogen	Journal of Thrombosis and Thrombolysis (2023)
	22/1 01:45 af gentogen	Thrombotic thrombocytopenic purpura (TTP) is a rare and life-threatening thrombotic microangiopathy.........Combination of daratumumab in the treatment of initial diagnosed acquired thrombotic thrombocytopenic purpura can rapidly restore ADAMST13 activity and turn negative for ADAMST13 inhibitors, resulting in long-term remission in patients.
	22/1 01:41 af gentogen	Blood Cells, Molecules, and Diseases Volume 99, March 2023, 102724
	22/1 01:40 af gentogen	Primary immune thrombocytopenia (ITP) in adult patients typically presents as a repeatedly relapsing disease in need of multiple lines of therapy. Here we report the clinical courses of two patients, an 82-year-old female and a 54-year-old male, with primary ITP after multiple relapses and exhausted standard therapies, which we treated with the myeloma-licensed anti-CD38 monoclonal antibody daratumumab in an off-label setting
	22/1 01:39 af gentogen	(link)
	22/1 01:39 af gentogen	OncoImmunology Volume 12, 2023 - Issue 1

	22/1 01:38 af gentogen	One patient with leptomeningeal PEL had a complete response to Dara and Pom combination treatment.
	22/1 01:38 af gentogen	Primary effusion lymphoma (PEL), an aggressive non-Hodgkin lymphoma caused by Kaposi sarcoma-associated herpesvirus (KSHV), lacks standard therapy and has a median survival of 10–22 months.....data presented here provide evidence to support a clinical trial of Dara in patients with refractory/relapsed PEL and in the future, potentially exploring the combination of Dara with ATRA, Pom, or other ADCC-enhancing therapy
	22/1 01:36 af gentogen	Lyder ganske imponerende...
	22/1 01:35 af gentogen	The second patient with proteinase 3-ANCA-positive granulomatosis with polyangiitis, diffuse alveolar haemorrhage necessitating extracorporeal membrane oxygenation (ECMO) and acute kidney failure, requiring kidney replacement therapy, was weaned off ECMO, mechanical ventilation and dialysis and discharged home after daratumumab
	22/1 01:34 af gentogen	(link)
	22/1 01:33 af gentogen	Treatment-refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a life-threatening condition without evidence-based treatment options.....Daratumumab was safe and effective in inducing remission in two patients with severe treatment-refractory AAV, warranting prospective clinical trials to establish safety and efficacy.
	21/1 16:55 af ProInvestorNEWS	God eftermiddag lørdag 21. jan. Hermed en teknisk status på det danske C25 index, hvor de eneste friske regnskabs-tal der er lagt ind, er for Chr. Hansen med deres Q1 2022/23 regnskab. Resten af regnskabs-tal er stadig fra Q3 2022. Lige pt. er Novozymes den case med best risk/reward. Vi har dog 14 selskaber i Daytrader porteføljen, så jeg vil ikke pt. tilføje flere selskaber. Nordicstock. (link)
	21/1 08:22 af Helge Larsen/PI-redaktør	Godmorgen. :-)
	20/1 16:21 af E L	they thought , if @gentogen posts it here, they may as well put it in clinicaltrials ;-)
	20/1 16:18 af E L	Expanded Access to Epcoritamab (link)
	20/1 12:02 af Solsen	Interessant tweet (link)
	20/1 11:35 af E L	the small Mayo Clinic Lupus trial is also mono i think, should have data this year. (link)
	20/1 11:31 af Bulder	Nu skal Janssen bare overtales til at sætte noget i gang med RA. Så vidt jeg husker foreligger der en IND. Men det kommer måske med hex38.
	20/1 11:25 af Bulder	Og så er det monoterapi. Måske endnu bedre udkomme i kombier. Belimumab nævnes i diskussionen.
	20/1 10:45 af Darvin	Der skulle stå: dukker op i flere og flere forsøg ;-)
	20/1 10:44 af Darvin	Dara dukker op i forsøg. Nu skal man nok ikke lige drage en parallel til Novo og fedme, men syntes efterhånden der er lagt i ovnen til flere sjove ting.
	20/1 10:40 af Darvin	Tak Gentogen. Bemærker sætningen yderst effektiv!
	20/1 09:06 af bibob	God morgen. :-)
	20/1 07:25 af Stroka	God morgen :-)
	20/1 07:14 af Helge Larsen/PI-redaktør	Godmorgen :-)
	20/1 00:49 af gentogen	These data suggest that Daratumumab administered alone (i.e., without any other immunosuppressant or agents targeting B-cell activating factor) is highly effective in RLN.......In summary, Daratumumab appears to be a new effective therapeutic tool for the management of Refractory Lupus Nephritis.
	19/1 23:25 af E L	Daratumumab monotherapy for refractory lupus nephritis (link)
	19/1 19:11 af ProInvestorNEWS	Correction to Company Announcement No. 1 of January 3, 2023 (link)
	19/1 18:39 af E L	Frontier4 concludes the clinical development program if i understand it correctly. really curious as to when they anticipate to have the data to file mim8
	19/1 18:18 af gentogen	(link)
	19/1 18:18 af gentogen	When and how often the participants will receive Mim8 in this study depends on the treatment participant receives in the current Mim8 study participant is taking part in. The study will last for up to 5.5 years. The duration of the study depends on when the participant enrolled in this study. The study will end if Mim8 is approved and marketed in participant's country during the study, or the study will end in 2028, whichever comes first.